MedTrace Logo

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

NCT04439539 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2025-06-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of a treatment regimen of JNJ-73763989 + pegylated interferon alpha-2a (PegIFN-alpha-2a) + nucleos(t)ide analog (NA).

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

JNJ-73763989

JNJ-73763989 injection will be administered subcutaneously.

DRUG

PegIFN-alpha-2a

PegIFN-alpha-2a injection will be administered subcutaneously.

DRUG

Tenofovir disoproxil

Tenofovir disoproxil film-coated tablet will be administered orally.

DRUG

Tenofovir alafenamide

Tenofovir alafenamide film-coated tablet will be administered orally.

DRUG

JNJ-56136379

JNJ-56136379 will be administered orally.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-14
Primary Completion
2023-08-29
Completion
2024-02-13
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Germany
  • Japan
  • Russia
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04439539 on ClinicalTrials.gov